Natera stock jumps after Japan approves Signatera for CRC testing.
Signatera becomes Japan’s first PMDA-approved CRC MRD test.
Natera plans a Japan commercial launch before the end of 2026.
GALAXY trial data backed Signatera’s Japan regulatory approval.
SRL will support Signatera rollout through Japan’s lab network.
Natera (NTRA) shares surged 7.67% to $252.79 after Japan approved Signatera for colorectal cancer patients receiving treatment after surgery. The approval makes Signatera Japan’s first authorized molecular residual disease test for colorectal cancer. Natera plans a commercial launch before the end of 2026, pending final pricing decisions.
Japan’s Pharmaceuticals and Medical Devices Agency approved Signatera for colorectal cancer patients in the adjuvant treatment setting. The test detects molecular residual disease through circulating tumor DNA found in a patient’s blood. Therefore, clinicians can assess whether cancer remains after surgery and guide further treatment decisions.
Japan records more than 150,000 colorectal cancer diagnoses annually, creating substantial demand for more personalized testing tools. The country faces a disease burden similar to the United States, where colorectal cancer remains common. Signatera could help Japanese doctors identify patients who may benefit from chemotherapy after surgery.
Japanese medical groups already support molecular residual disease testing for colorectal cancer management. The Japan Society of Clinical Oncology issued a position supporting its use in clinical care. Meanwhile, the Japanese Society of Medical Oncology included similar guidance for treatment planning.
Natera supported its regulatory application with findings from the GALAXY clinical trial in Japan. Researchers analyzed 2,240 samples from patients with surgically removable colorectal cancer. The study formed part of CIRCULATE-Japan, which includes thousands of patients across more than 150 institutions.
The trial found that MRD-positive patients gained significant benefits from chemotherapy following surgery. MRD-negative patients received no measurable benefit from the same treatment approach. These results could help doctors reduce unnecessary chemotherapy while directing treatment toward higher-risk patients.
GALAXY ranks among the largest prospective studies evaluating molecular residual disease testing in resectable colorectal cancer. Its size provided Natera with broad clinical evidence supporting Signatera’s role in treatment decisions. The Japanese research network strengthened the findings within the country’s healthcare setting.
SRL will manage Signatera’s commercialization as Natera’s exclusive business partner in Japan. The diagnostic company operates a nationwide laboratory network serving hospitals and other healthcare providers. Its infrastructure could support broad test access after Natera completes pricing arrangements.
SRL belongs to H.U. Group Holdings and operates as Japan’s largest reference laboratory. The company will help hospitals introduce Signatera into routine colorectal cancer care. Natera expects the commercial launch to occur later in 2026 after authorities establish final pricing.
Natera also plans to expand Signatera’s regulatory reach into other cancer types within Japan. Muscle-invasive bladder cancer represents the company’s next planned submission in the country. Meanwhile, NTRA’s 7.67% rise reflected the market response to the approval and planned Japanese launch.
The post Natera, Inc. (NTRA) Stock: Surges 7% as Signatera Wins Japan Approval appeared first on CoinCentral.
